AAT Augmentation denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied AAT Augmentation as Duplicate Therapy

Blue Cross Blue Shield's duplicate-therapy edit flags a claim when its system detects that another agent addressing the same deficiency or condition is already active on your profile. For alpha-1 antitrypsin (AAT) augmentation therapy — an intravenous protein replacement used in alpha-1 antitrypsin deficiency (AATD) — this denial is unusual in a strict clinical sense: AAT augmentation has no true therapeutic equivalent. The denial may reflect an administrative or billing-code overlap rather than a genuine clinical duplication.

This type of denial is frequently resolvable once the insurer understands the clinical picture. AAT augmentation therapy is the only established treatment that directly addresses the protein deficiency underlying AATD lung disease. If BCBS is detecting another claim as a "duplicate," your appeal should clarify — with clinical specificity — why the two therapies are not duplicative.

## Federal Appeal Rights

• ACA §2719 external review: If internal appeal fails, you are entitled to an independent external review by an accredited IRO. File within the deadline in your denial notice — typically around four months from the denial date per your plan documents.
• ERISA §503 (self-funded plans): Requires full and fair internal review with written reasoning explaining the duplicate-therapy determination.
• Expedited review: If interruption of AAT augmentation therapy poses a health risk, request expedited processing in writing.

## Concrete Appeal Steps

1. Obtain the denial letter and EOB. Identify which specific drug or claim BCBS is treating as the duplicate. 2. Request BCBS's duplicate-therapy policy criteria in writing. 3. Contact your prescriber and the dispensing specialty pharmacy to confirm there is no administrative overlap (e.g., two claims for the same infusion from different billing entities). 4. If the denial reflects a genuine misidentification, have your prescriber submit a clarifying letter explaining that no therapeutic duplication exists. 5. Submit an internal appeal within your plan's deadline with the documentation package below. 6. Escalate to external review if internal appeal fails.

## Documentation to Gather

• Diagnosis confirmation: Records confirming the AATD diagnosis, including genotype testing results (your prescriber will know what is relevant here).
• Prior-treatment history: A summary of the AATD treatment history, including when augmentation therapy was initiated and any other AATD-related treatments that may have triggered the duplicate-therapy flag.
• Clinical-severity documentation: Pulmonary function records, imaging, and chart notes documenting the severity of the underlying lung disease that makes augmentation therapy necessary.
• Prescriber medical-necessity letter: A letter specifically addressing the duplicate-therapy determination — identifying what BCBS flagged as a duplicate, explaining why it is not therapeutically duplicative, and confirming that AAT augmentation is the clinically indicated and non-duplicable treatment for this patient.

## Criteria-Mapping Structure

| BCBS Duplicate-Therapy Criterion | Documentation Rebutting the Duplication Finding | |---|---| | Copy the duplicate-therapy policy language from the BCBS policy | Prescriber letter explaining the distinct clinical role of AAT augmentation | | The specific agent BCBS identified as a duplicate | Clarification of why the two therapies are not interchangeable | | Any coverage-exception provision for medically necessary non-duplicative therapy | Chart documentation supporting individualized medical necessity |

Contact BCBS's clinical review team directly — duplicate-therapy edits for rare-disease therapies like AAT augmentation are sometimes resolved at the pre-appeal peer-to-peer stage, which your prescriber can request before a formal appeal is needed.